Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes

Empagliflozin, a sodium-glucose co-transporter (SGLT) inhibitor, reduces heart failure and sudden cardiac death but the underlying mechanisms remain elusive. In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction. We hypothesise th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Kwong-Man, Lau, Yee-Man, Dhandhania, Vidhu, Cai, Zhu-Jun, Lee, Yee-Ki, Lai, Wing-Hon, Tse, Hung-Fat, Siu, Chung-Wah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173708/
https://www.ncbi.nlm.nih.gov/pubmed/30291295
http://dx.doi.org/10.1038/s41598-018-33293-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173708/
https://www.ncbi.nlm.nih.gov/pubmed/30291295
http://dx.doi.org/10.1038/s41598-018-33293-2

Ejemplares similares